Artiva Biotherapeutics has a total of 9 patents globally, out of which no patents have been granted. Of these 9 patents, all patents are active. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Artiva Biotherapeutics.
Artiva Biotherapeutics was founded in the year 2019. The Company provides health care services. The Company focuses on developing and commercializing off-the-shelf cell therapies for patients with hematologic malignancies and solid tumors.
Do read about some of the most popular patents of Artiva Biotherapeutics which have been covered by us in this article and also you can find Artiva Biotherapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Artiva Biotherapeutics patent portfolio.
How many patents does the founder and the CEO of Artiva Biotherapeutics have?
The founder Peter Flynn has 27 patents and Tom Farrell has 16 patents. The CEO Fred Aslan has 0 patent.
How many patents does Artiva Biotherapeutics have?
Artiva Biotherapeutics has a total of 9 patents globally. These patents belong to 7 unique patent families. Out of 9 patents, all patents are active.
How Many Patents did Artiva Biotherapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Artiva Biotherapeutics Applications Filed | Artiva Biotherapeutics Patents Granted |
| 2022 | 6 | – |
| 2021 | 3 | – |
How many Artiva Biotherapeutics patents are Alive/Dead?
All the Patents were filed by Artiva Biotherapeutics are Dead.
Where are Research Centres of Artiva Biotherapeutics Patents Located?
The Research Centre for all the Artiva Biotherapeutics patents is the United States of America.
List of Artiva Biotherapeutics Patents
| Artiva Biotherapeutics Patents | Title |
| WO2022216811A3 | Chimeric Antigen Receptor Comprising An Anti-Cd19 Antibody Or Antigen-Binding Fragment Thereof And Natural Killer Cells Comprising The Same |
| WO2022216815A1 | Treatment Of Cancer With Nk Cells And A Cd20 Targeted Antibody |
| WO2022216826A1 | Treatment Of Cancer With Nk Cells And A Cd38-Targeted Antibody |
| WO2022216813A1 | Chimeric Antigen Receptor Comprising An Anti-Her2 Antibody Or Antigen-Binding Fragment Thereof And Natural Killer Cells Comprising The Same |
| WO2022216837A1 | Treatment Of Cancer With Nk Cells And An Egfr Targeted Antibody |
| WO2022216831A1 | Treatment Of Cancer With Nk Cells And A Her2 Targeted Antibody |
| WO2022133056A9 | Expanded And Stimulated Natural Killer Cells |
| WO2022133061A9 | Infusion Ready Cryopreservation Compositions |
| WO2022133057A1 | Treatment Of Cancer With Nk Cells And A Cd20 Targeted Antibody |